A Novel CBP/p300 Inhibitor for the Treatment of AR-driven Cancers

Time: 1:30 pm
day: Day One


  • Presenting a novel CBP/p300 inhibitor which antagonizes AR signalling
  • Analyzing the efficacy of the drug in several models of AR-driven tumors in vitro and in vivo
  • It is currently in Ph1 clinical trial in prostate cancer